Join
Live feed
·
PRReleasevia Quantisnow
Apellis Pharmaceuticals Inc. logo

Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023

ByQuantisnow·Wall Street's wire, on your screen.
APLS· Apellis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APLS (Apellis Pharmaceuticals Inc.) and more on Quantisnow.